Home > Boards > US Listed > Biotechs >

Intellia Therapeutics Inc. (NTLA)

NTLA RSS Feed
Add NTLA Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 5/2/2022 12:06:00 PM - Followers: 14 - Board type: Free - Posts Today: 0

Intellia Therapeutics, Inc. is a United States-based genome editing company focused on the development of curative therapeutics using a biological tool, CRISPR/Cas9 system. The Company's CRISPR/Cas9 technology edits diseased genes in the human body through a single treatment course. It focuses on the therapeutic applications of CRISPR/Cas9 genome editing. Its portfolio includes CRISPR/Cas9 platform technology, delivery technologies and nucleic acid modifications for human therapeutic use. The Company's CRISPR/Cas9 platform components include the guide ribonucleic acid (RNA) and the Cas9 nuclease (the genetic scissors). It has access to various delivery modalities specific to various in vivo and ex vivo approaches. The Company focuses on engineering ex vivo CRISPR/Cas9 cell therapies for chimeric antigen receptor T cell (CAR-T) and hematopoietic stem cell (HSC) applications. It also focuses on the use of in vivo Lipid Nanoparticle (LNP) delivery technology.
NTLA
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
NTLA News: Investing in These 3 Healthcare Stocks Could Double Your Money, Says Credit Suisse 05/10/2022 04:26:05 AM
NTLA News: Brookline Capital Markets Thinks Intellia Therapeutics’ Stock is Going to Recover 05/09/2022 03:52:49 AM
NTLA News: 3 Analyst’s Top Stocks with Huge Upside Potential 05/08/2022 10:23:07 PM
NTLA News: Intellia Therapeutics (NTLA) Receives a Buy from SVB Securities 05/08/2022 07:11:44 AM
NTLA News: Analysts Conflicted on These Healthcare Names: Cigna (CI), Intellia Therapeutics (NTLA) and Dynavax (DVAX) 05/06/2022 07:05:50 PM
PostSubject
#31   New preclinical data https://www.globenewswire.com/news-release/2022/05/02/24333 jondoeuk 05/02/22 12:06:00 PM
#30   Also, https://jitc.bmj.com/content/8/Suppl_3/A103.2 jondoeuk 02/13/22 08:08:33 PM
#29   https://www.fiercebiotech.com/research/engineered-tcr-t-cells-by-fred-hutch-san- jondoeuk 02/09/22 06:18:02 PM
#28   ASH abstracts jondoeuk 11/04/21 02:17:49 PM
#27   PR https://www.globenewswire.com/news-release/2021/10/20/2317270/0/en/Intellia-T jondoeuk 10/20/21 03:16:26 PM
#26   The company will present new data at the jondoeuk 10/12/21 12:42:29 PM
#25   The company has announced that it has submitted jondoeuk 08/05/21 01:03:06 PM
#24   And BEAM Glider549 06/30/21 12:05:40 PM
#23   Sudden burst in genomic stocks. NTLA, EDIT, CRSP Gpheart2016 06/30/21 11:22:23 AM
#22   Big gap and lot of money to be make it happen 06/29/21 07:02:03 AM
#21   You do understand that this is a biotech go_glortho 06/28/21 05:41:00 PM
#20   Large negatives across the board. Revenue Per Share $0.86 make it happen 06/28/21 11:57:06 AM
#19   Blackstone Life Sciences, Cellex Cell Professionals, and Intellia jondoeuk 06/24/21 03:30:19 PM
#18   Adding CD8 coreceptors may enhance CD4+ T-cell responses jondoeuk 04/30/21 09:59:09 PM
#17   Knock-ins, knockdowns and/or overexpression are other ways to jondoeuk 04/30/21 09:50:55 PM
#16   In the setting of established and (rapidly) proliferating jondoeuk 04/30/21 09:43:58 PM
#15   This was presented at SITC last year https://jitc.bmj.com/content/8/Suppl_3/A103 jondoeuk 04/30/21 04:21:06 PM
#14   This trial showed that donor-derived, CD8+ T-cells engineered jondoeuk 04/30/21 04:19:29 PM
#13   https://www.businesswire.com/news/home/20210107005234/en/ArsenalBio-Announces-Mu jondoeuk 01/09/21 05:49:48 PM
#12   Cathie Wood likes some cutting edge Gene editing Fress 01/07/21 10:28:57 AM
#11   NTLA 5001, a T Cell Product Candidate with jondoeuk 12/05/20 01:22:47 PM
#10   Arsenal Bio [1] is also using it for jondoeuk 11/25/20 02:59:16 PM
#9   Currently, the company is using CRISPR/Cas9 screening to jondoeuk 11/25/20 02:58:37 PM
#8   Preclinical data (at ASH) https://ashpublications.org/blood/article/136/Suppleme jondoeuk 11/04/20 06:06:01 PM
#7   Bought more at $18.30 before selling all @ chmcnfunds 01/08/18 01:50:15 PM
#6   CRISPR hits a snag: Our immune systems may chmcnfunds 01/08/18 10:57:51 AM
#5   In at $18.90. Got to believe the drop chmcnfunds 01/08/18 10:56:50 AM
#4   I don't have enough understanding on how the rule_rationale 10/09/17 01:19:13 PM
#3   Am I the only one that thinks this jimski55 10/06/17 03:38:42 PM
#2   Which of the big three is closest to redspinelpinktopaz 03/07/17 02:18:43 PM
#1   Took a starter here, CRISPR could do amazing things! rule_rationale 05/10/16 11:00:34 AM
PostSubject
Consent Preferences